Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

36 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06955156 2025-05-02

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Phase 2 Recruiting

50 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

132 enrolled

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05978648 2023-11-30

SMA-BC-002

Phase 2 Recruiting

116 enrolled

Breast

Breast Neoplasms

NCT05862610 2023-07-24

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Breast Neoplasms

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

I-SPY

ToPCourT

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Myeloprotection With Trilaciclib in Pan-cancer Population

SMA-BC-002

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)